Second generation antipsychotic-induced weight gain in youth with autism spectrum disorders: a brief review of mechanisms, monitoring practices, and indicated treatments

References

• American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. 2004. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27, 596–601.
   PubMed Web of Science ®Google Scholar
• Anagnostou E, Aman M, Handen B, Sanders K, Shui A, Hollway J, Brian J, Arnold L, Capano L, Hellings J, Butter E, Mankad D, Tumuluru R, Kettel J, Newsom C, Hadjiyannakis S, Peleg N, Odrobina D, McAuliffe-Bellin S, Zakroysky P, Marler S, Wagner A, Wong T, Macklin E, Veenstra-VanderWeele J. 2016. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: A randomized clinical trial. JAMA Psychiatry, 73, 928–937. DOI: 10.1001/jamapsychiatry.2016.1232
   PubMed Web of Science ®Google Scholar
• Arango C, Robles O, Parellada M, Fraguas D, Ruiz-Sancho A, Medina O, Zabala A, Bombín I, Moreno D. 2009. Olanzapine compared to quetiapine in adolescents with first psychotic episode. European Child and Adolescent Psychiatry, 18, 418–428.
   PubMed Web of Science ®Google Scholar
• Arman S, Sadramely M, Nadi M, Koleini N. 2008. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. Saudi Medical Journal, 29, 1130–1134.
   PubMed Web of Science ®Google Scholar
• Bahr S, Tyler B, Wooldridge N, Butcher B, Burns T, Teesch L, Oltman C, Azcarate-Peril M, Kirby J, Calarge C. 2015. Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. Translational Psychiatry, 5, e652. Available through: PubMed database [Accessed 5 June 2019].
   PubMed Web of Science ®Google Scholar
• Baptista T, Martinez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, Arapé Y, Martinez M, de Mendoza S, Teneud L, Hernández L. 2006. Metformin for prevention of weight gain and insulin resistance with olanzapine: A double-blind placebo-controlled trial. Canadian Journal of Psychiatry, 51, 192–196.
   PubMed Web of Science ®Google Scholar
• Baptista T, Rangel N, Fernandez V, Carrizo E, El Fakih Y, Uzcátegui E, Galeazzi T, Gutiérrez M, Servigna M, Dávila A, Uzcátegui M, Serrano A, Connell L, Beaulieu S, de Baptista E. 2007. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind placebo-controlled trial. Schizophrenia Research, 93, 99–108.
   PubMed Web of Science ®Google Scholar
• Barnes T, Paton C, Cavanagh M, Hancock E, Taylor D. 2007. A UK audit of screening for the metabolic side effects of antipsychotics in community patients. Schizophrenia Bulletin, 33, 1397–1403.
   PubMed Web of Science ®Google Scholar
• Bean M. K, Stewart K, Olbrisch ME. 2008. Obesity in America: Implications for clinical and health psychologists. Journal of Clinical Psychology in Medical Settings, 15, 214–224.
   PubMed Web of Science ®Google Scholar
• Bushe C, Slooff C, Haddad P, Karagianis J. 2012. Weight change from 3-year observational data: Findings from the worldwide schizophrenia outpatient health outcomes database. Journal of Clinical Psychiatry, 73, e749–755.
   PubMedGoogle Scholar
• Caemmerer J, Correll C, Maayan L. 2012. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. Schizophrenia Research, 140, 159–168.
   PubMed Web of Science ®Google Scholar
• Canitano R. 2005. Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders. Brain Development, 27, 228–232.
   PubMed Web of Science ®Google Scholar
• Carrizo E, Fernandez V, Connell L, Sandia I, Prieto D, Mogollón J, Valbuena D, Fernández I, de Baptista E, Baptista T. 2009. Extended release metformin for metabolic control assistance during prolonged clozapine administration: A 14 week, double-blind, parallel group, placebo-controlled study. Schizophrenia Research, 113, 19–26.
   PubMed Web of Science ®Google Scholar
• Chen C, Chiu C, Huang M, Wu T, Liu H, Lu M. 2008. Metformin for metabolic dysregulation in schizophrenic patients treated with olanzapine. Progress in Neuropsychopharmacology and Biological Psychiatry, 32, 925–931.
   PubMed Web of Science ®Google Scholar
• Correll C. 2005. Metabolic side effects of second-generation antipsychotics in children and adolescents: A different story. Journal of Clinical Psychiatry, 66, 1331–1332.
   PubMed Web of Science ®Google Scholar
• Correll C, Carlson H. 2006. Endocrine and metabolic adverse effects of psychotropic medication in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 771–791.
   PubMed Web of Science ®Google Scholar
• Davey K, O’Mahony S, Schellekens H, O'Sullivan O, Bienenstock J, Cotter P, Dinan T, Cryan J. 2012. Gender-dependent consequences of chronic olanzapine in the rat: Effects on body weight, inflammatory, metabolic, and microbiota parameters. Psychopharmacology, 221(1), 155–169.
   PubMed Web of Science ®Google Scholar
• De Hert M, Dobbelaere M, Sheridan E, Cohen D, Correll C. 2011. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry, 26, 144–158.
   PubMed Web of Science ®Google Scholar
• de Silva V, Dayabandara M, Wijesundara H, Henegama T, Gunewardena H, Suraweera C, Hanwella R. 2015. Metformin for treatment of antipsychotic-induced weight gain in a south asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study. Journal of Psychopharmacology, 29, 1255–1261.
   PubMed Web of Science ®Google Scholar
• de Silva V, Suraweera C, Ratnatunga S, Dayabandara M, Wanniarachchi N, Hanwella R. 2016. Metformin in prevention and treatment of antipsychotic induced weight gain: A systematic review and meta analysis. BMC Psychiatry, 16, 1–10. DOI: 10.1186/s12888-016-1049-5
   PubMed Web of Science ®Google Scholar
• Giles M, Wilke A, Kopf D, Nonell A, Lehnert H, Deuschle M. 2005. Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: Implications for atypical antipsychotics. Psychosomatic Medicine, 67, 748–751.
   PubMed Web of Science ®Google Scholar
• Goltz J, Rice T. 2017. Commentary: A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. Frontiers in Psychiatry, 8, 59.
   PubMed Web of Science ®Google Scholar
• Haas M, Delbello M, Pandina G, Kushner S, Van Hove I, Augustyns I, Quiroz J, Kusumakar V. 2009a. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: A randomized, double-blind, placebo-controlled study. Bipolar Disorder, 11, 687–700.
   PubMed Web of Science ®Google Scholar
• Haas M, Eerdekens M, Kushner S, Singer J, Augustyns I, Quiroz J, Pandina G, Kusumakar V. 2009b. Efficacy, safety, and tolerability of two risperidone dosing regimens in adolescent schizophrenia: Double-blind study. British Journal of Psychiatry, 194, 158–164.
   PubMed Web of Science ®Google Scholar
• Handen B, Anagnostou E, Aman M, Sanders K, Chan J, Hollway J, Brian J, Arnold L, Capano L, Williams C, Hellings J, Butter E, Mankad D, Tumuluru R, Kettel J, Newsom C, Peleg N, Odrobina D, McAuliffe-Bellin S, Marler S, Wong T, Wagner A, Hadjiyannakis S, Macklin EA, Veenstra-VanderWeele J. 2017. A randomized, placebo-controlled trial of metformin for the treatment of overweight induced by antipsychotic medication in young people with autism spectrum disorder: Open-label extension. Journal of the American Academy of Child and Adolescent Psychiatry, 56, 849–856.
   PubMed Web of Science ®Google Scholar
• Hellings J, Zarcone J, Crandall K, Wallace D, Schroeder S. 2001. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. Journal of the American Academy of Child and Adolescent Psychiatry, 11, 229–238.
   Google Scholar
• Hewitt K, Lee M, Dourish C, Clifton P. 2002. Serotonin 2C receptor agonists and the behavioural satiety sequence in mice. Pharmacology, Biochemistry, and Behavior, 71, 691–700.
   PubMed Web of Science ®Google Scholar
• Hoffman L, Rice T. 2012. Psychodynamic considerations in the treatment of a young person with autistic spectrum disorder: A case report. Journal of Infant, Child, and Adolescent Psychotherapy, 11, 67–85.
   Google Scholar
• Ichikawa H, Mikami K, Okada T, Yamashita Y, Ishizaki Y, Tomoda A, Ono H, Usuki C, Tadori Y. 2017. Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: A randomized, double-blind, placebo-controlled study. Child Psychiatry and Human Development, 48, 196–806.
   Web of Science ®Google Scholar
• Jarskog L, Hamer R, Catellier D, Stewart D, Lavange L, Ray N, Golden L, Lieberman J, Stroup T. 2013. Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. The American Journal of Psychiatry, 170, 1–17.
   PubMed Web of Science ®Google Scholar
• Kirino, E. 2014. Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children. Clinical Medicine Insights: Pediatrics, 8, 17–30.
   PubMedGoogle Scholar
• Klein D, Cottingham E, Sorter M, Barton B, Morrison J. 2006. A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents. The American Journal of Psychiatry, 163, 2072–2079. 2006.163.12.2072 2.
   PubMed Web of Science ®Google Scholar
• Kroeze W, Hufeisen S, Popadak B, Renock S, Steinberg S, Ernsberger P, Jayathilake K, Meltzer H, Roth B. 2003. H1-Histamine receptor affinity predicts short term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology, 28, 519–526.
   PubMed Web of Science ®Google Scholar
• Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D, Keefe R, Davis S, Davis C, Lebowitz B, Severe J, Hsiao J. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–1223.
   PubMed Web of Science ®Google Scholar
• Maayan L, Correll C. 2011. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents. Journal of Child and Adolescent Psychopharmacology, 21, 517–535.
   PubMed Web of Science ®Google Scholar
• Maayan L, Correll C. 2010. Management of antipsychotic related weight gain. Expert Review of Neurotherapeutics, 10, 1175–1200.
   PubMed Web of Science ®Google Scholar
• Magrani J, de Castro e Silva E, Varjao B, Duarte G, Ramos A, Athanazio R, Barbetta M, Luz P, Fregoneze J. 2004. Histaminergic H1 and H2 receptors located within the ventromedial hypothalamus regulate food and water intake in rats. Pharmacology, Biochemistry, and Behavior, 79, 189–198.
   PubMed Web of Science ®Google Scholar
• Marcus R, Owen R, Kamen L, Manos G, McQuade R, Carson W, Aman M. 2009. A placebo-controlled fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 1110–1119.
   PubMed Web of Science ®Google Scholar
• Martinez-Ortega J, Funes-Godoy S, Diaz-Atienza F, Gutierrez-Rojas L, Perez-Costillas L, Gurpegui M. 2013. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: A critical review. European Child and Adolescent Psychiatry, 22, 457–479.
   PubMed Web of Science ®Google Scholar
• McCracken J, McGough J, Shah B, Cronin P, Hong D, Aman M, Arnold L, Lindsay R, Nash P, Hollway J, McDougle C, Posey D, Swiezy N, Kohn A, Scahill L, Martin A, Koenig K, Volkmar F, Carroll D, Lancor A, Tierney E, Ghuman J, Gonzalez N, Grados M, Vitiello B, Ritz L, Davies M, Robinson J, McMahon D. 2002. Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314–321.
   PubMed Web of Science ®Google Scholar
• Mclellan J, Stock S, American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). 2013. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 52, 976–990.
   PubMed Web of Science ®Google Scholar
• Morrato E, Cuffel B, Newcomer J, Lombardo I, Kamat S, Barron J. 2009. Metabolic risk status and second-generation antipsychotic drug selection: A restrospective study of commercially insured patients. Journal of Clinical Psychopharmacology, 29, 26–32.
   PubMed Web of Science ®Google Scholar
• Morrato E, Nicol G, Maahs D, Druss B, Hartung D, Valuck R, Campagna E, Newcomer J. 2010. Metabolic screening in children receiving antipsychotic drug treatment. Archives of Pediatrics and Adolescent Medicine, 164, 344–351.
   PubMed Web of Science ®Google Scholar
• Morrison J, Cottingham E, Barton B. 2002. Metformin for weight loss in pediatric patients taking psychotropic drugs. The American Journal of Psychiatry, 159, 655–657.
   PubMed Web of Science ®Google Scholar
• Mostafavi S, Solhi M, Mohammadi M, Akhondzadeh S. 2017. Melatonin for reducing weight gain following administration of atypical antipsychotic olanzapine for adolescents with bipolar disorder: A randomized, double-blind, placebo-controlled trial. Journal of Child and Adolescent Psychopharmacology, 27, 440–444.
   PubMed Web of Science ®Google Scholar
• Olfson M, Blanco C, Liu S, Wang S, Correll C. 2012. National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Archives of General Psychiatry, 69, 1247–1256.
   PubMed Web of Science ®Google Scholar
• Owen R, Sikich L, Marcus R, Corey-Lisle P, Manos G, McQuade R, Carson W, Findling R. 2009. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124, 1533–1540.
   PubMed Web of Science ®Google Scholar
• Parikh M, Kolevzon A, Hollander E. 2008. Psychopharmacology of aggression in children and adolescents with autism: A critical review of efficacy and tolerability. Journal of the American Academy of Child and Adolescent Psychiatry, 18, 157–178.
   Google Scholar
• Park S, Cervesi C, Galling B, Molteni S, Walyzada F, Ameis S, Gerhard T, Olfson M, Correll C. 2016. Antipsychotic use trends in youth with autism spectrum disorder and/or intellectual disability: A meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 55, 456–468.
   PubMed Web of Science ®Google Scholar
• Porfirio M, Gomes de Almeida J, Stornelli M, Giovinazzo S, Purper-Ouakil D, Masi G. 2017. Can melatonin prevent or improve metabolic side effects during antipsychotic treatments? Neuropsychiatric Disease and Treatment, 13, 2167–2174.
   PubMed Web of Science ®Google Scholar
• Rado J, Cavanaugh S. 2016. A naturalistic randomized placebo-controlled trial of extended-release metformin to prevent weight gain associated with olanzapine in a US community-dwelling population. Journal of Clinical Psychopharmacology, 36, 163–168.
   PubMed Web of Science ®Google Scholar
• Rezaei V, Mohammadi M, Ghanizadeh A, Sahraian A, Tabrizi M, Rezazadeh S, Akhondzadeh S. 2010. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in Neuropsychopharmacology and Biological Psychiatry, 34, 1269–1272.
   PubMed Web of Science ®Google Scholar
• Rice T. 2018. Commentary: Altered medial frontal and superior temporal response to implicit processing of emotions in autism. Research in Autism Spectrum Disorders, 52, 34–36.
   Web of Science ®Google Scholar
• Roerig J, Steffen K, Mitchell J. 2011. Atypical antipsychotic-induced weight gain: Insights into mechanisms of actions. CNS Drugs, 25, 1035–1059.
   PubMed Web of Science ®Google Scholar
• Salau M, Adam B, Coffey B. 2015. Metformin in an adolescent with significant weight gain. Journal of Child and Adolescent Psychopharmacology, 25, 589–592.
   PubMed Web of Science ®Google Scholar
• Shapiro M, Reid A, Olsen B, Taasan M, McNamara J, Nguyen M. 2015. Topiramate, zonisamide and weight loss in children and adolescents prescribed psychiatric medications: A medical record review. The International Journal of Psychiatry in Medicine, 51, 56–68.
   Web of Science ®Google Scholar
• Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, Dunbar F. 2004. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634–e641.
   PubMed Web of Science ®Google Scholar
• Shin L, Bregman H, Breeze J, Noyes N, Frazier J. 2009. Metformin for weight control in pediatric patients on atypical antipsychotic medication. Journal of Child and Adolescent Psychopharmacology, 19, 275–279.
   PubMed Web of Science ®Google Scholar
• Skonieczna-Zydecka K, Marlicz W, Misera A, Koulaouzidis A, Łoniewski I. 2018. Microbiome- the missing link in the gut-brain axis: Focus on its role in gastrointestinal and mental health. Journal of Clinical Medicine, 7, E521. Available through: PubMed database [Accessed 5 June 2019].
   PubMed Web of Science ®Google Scholar
• Swallen K. C, Reither E. N, Haas S. A, Meier A. M. 2005. Overweight, obesity, and health-related quality of life among adolescents: The national longitudinal study of adolescent health. Pediatrics, 115, 340–347.
   PubMed Web of Science ®Google Scholar
• Tramontina S, Zeni C, Pheula G, Rohde L. 2007. Topiramate in adolescents with juvenile bipolar disorder presenting weight gain due to atypical antipsychotics or mood stabilizers: An open clinical trial. Journal of Child and Adolescent Psychopharmacology, 17, 129–134.
   PubMed Web of Science ®Google Scholar
• Vickers S, Clifton P, Dourish C, Tecott L. 1999. Reduced satiating effect of d-fenfluramine in serotonin 5HT-2C receptor mutant mice. Psychopharmacology, 143, 309–314.
   PubMed Web of Science ®Google Scholar
• Wang M, Tong J, Zhu G, Liang G, Yan H, Wang X. 2012. Metformin for treatment of antipsychotic-induced weight gain: A randomized placebo-controlled study. Schizophrenia Research, 138, 54–57.
   PubMed Web of Science ®Google Scholar
• Weaver L, De Leon D, Borgmann-Winter K, Coffey B. 2010. Use of metformin to control clozapine-associated weight gain in an adolescent with schizoaffective disorder. Journal of Child and Adolescent Psychopharmacology, 20, 153–157.
   PubMed Web of Science ®Google Scholar
• Wink L, Adams R, Pedapati E, Dominick K, Fox E, Buck C, Erickson C. 2017. Brief report: Metformin for antipsychotic-induced weight gain in youth with autism spectrum disorder. Journal of Autism and Developmental Disorders, 47, 2290–2294. DOI: 10.1007/s10803-017-3132-2
   PubMedGoogle Scholar
• Wink L, Early M, Schaefer T, Pottenger A, Horn P, McDougle C, Erickson C. 2014. Body mass index change in autism spectrum disorders: Comparison of treatment with risperidone and aripiprazole. Journal of the American Academy of Child and Adolescent Psychiatry, 24, 78–82.
   Google Scholar
• Wozniak J, Mick E, Waxmonsky J, Kotarski M, Hantsoo L, Biederman J. 2009. Comparison of open-label, 8 week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. Journal of Child and Adolescent Psychopharmacology, 19, 539–545.
   PubMed Web of Science ®Google Scholar
• Wu R, Jin H, Gao K, Twamley E, Ou J, Shao P, Wang J, Guo X, Davis J, Chan P, Zhao J. 2012. Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first episode schizophrenia: A double-blind, randomized, placebo-controlled study. The American Journal of Psychiatry, 169, 813–821.
   PubMed Web of Science ®Google Scholar
• Wu R, Zhao J, Guo X, He Y, Fang M, Guo W, Chen J, Li L. 2008. Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double blind-placebo-controlled study. The American Journal of Psychiatry, 165, 352–358.
   PubMed Web of Science ®Google Scholar
• Wu R, Zhao J, Jin H, Shao P, Fang M, Guo X, He Y, Liu Y, Chen J, Li L. 2008. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: A randomized control trial. JAMA, 299, 185–193.
   PubMed Web of Science ®Google Scholar
• Yoon Y, Wink L, Pedapati E, Horn P, Erickson C. 2016. Weight gain effects of second-generation antipsychotic treatment in autism spectrum disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 822–827.
   Google Scholar
• Zheng W, Li X, Tang Y, Xiang Y, Wang C, de Leon J. 2015. Metformin for weight gain and metabolic abnormalities associated with antipsychotic treatment: Meta-analysis of randomized placebo-controlled trials. Journal of Clinical Psychopharmacology, 35, 499–509.
   PubMed Web of Science ®Google Scholar